Neurocrine Beats Q1 Forecast, Shares Jump 8%

Neurocrine reported Q1 adjusted earnings of $1.94 per share, surpassing the $1.17 consensus by $0.77 for the quarter.
Revenue reached $811.0 million, topping the $766.85 million forecast and marking a 44% year‑over‑year rise from $563.7 million in the comparable period.
Flagship drug INGREZZA generated $656.9 million in net sales, up 20% YoY, while CRENESSITY contributed $153.3 million with roughly 80% reimbursement for the quarter.
Neurocrine announced a definitive agreement to acquire Soleno Therapeutics for $2.9 billion, adding VYKAT XR and targeting a Q2 2026 close of the transaction.